Athersys, Inc. (NASDAQ:ATHX) has earned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.

Brokerages have set a one year consensus target price of $12.00 for the company and are expecting that the company will post ($0.08) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Athersys an industry rank of 115 out of 265 based on the ratings given to its competitors.

A number of equities analysts have weighed in on ATHX shares. Maxim Group set a $12.00 target price on Athersys and gave the stock a “buy” rating in a research note on Thursday, October 5th. Zacks Investment Research upgraded Athersys from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research report on Thursday, September 7th. Finally, ValuEngine lowered Athersys from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd.

WARNING: This report was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/11/13/brokerages-set-12-00-price-target-for-athersys-inc-athx.html.

Shares of Athersys (NASDAQ:ATHX) traded up $0.01 during midday trading on Monday, reaching $1.87. The company’s stock had a trading volume of 672,900 shares, compared to its average volume of 1,057,433. Athersys has a fifty-two week low of $1.02 and a fifty-two week high of $2.63.

In other news, EVP John J. Harrington sold 15,000 shares of the stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $2.17, for a total transaction of $32,550.00. Following the transaction, the executive vice president now directly owns 679,416 shares in the company, valued at approximately $1,474,332.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 9.40% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Athersys by 9.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,265,772 shares of the biopharmaceutical company’s stock valued at $6,441,000 after acquiring an additional 366,572 shares during the period. State Street Corp boosted its holdings in Athersys by 27.2% during the 2nd quarter. State Street Corp now owns 1,432,695 shares of the biopharmaceutical company’s stock valued at $2,161,000 after acquiring an additional 305,944 shares during the period. Northern Trust Corp boosted its holdings in Athersys by 30.8% during the 2nd quarter. Northern Trust Corp now owns 1,123,870 shares of the biopharmaceutical company’s stock valued at $1,697,000 after acquiring an additional 264,549 shares during the period. Geode Capital Management LLC boosted its holdings in Athersys by 35.2% during the 1st quarter. Geode Capital Management LLC now owns 756,004 shares of the biopharmaceutical company’s stock valued at $1,292,000 after acquiring an additional 196,981 shares during the period. Finally, Mckinley Capital Management LLC Delaware purchased a new stake in Athersys during the 3rd quarter valued at about $1,093,000. Institutional investors own 19.33% of the company’s stock.

About Athersys

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Get a free copy of the Zacks research report on Athersys (ATHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.